REZVOGLAR

Rezvoglar (insulin glargine-aglr), the second biosimilar of Lantus, was approved by the FDA in December 2021. As of late 2022, it is deemed interchangeable with Lantus and is a long-acting insulin that aids in regulating blood sugar levels.

Semglee has received FDA approval for the identical purposes as Lantus. These purposes encompass the regulation of blood sugar levels in both adults and children diagnosed with Type 1 diabetes, as well as in adults diagnosed with Type 2 diabetes.

Rezvoglar has become the second interchangeable biosimilar insulin to be approved in the United States. It follows the approval of Semglee, the first interchangeable biosimilar to Lantus, which was approved by the FDA on July 28, 2021.

Starting April 1, 2023, RezvoglarTM (insulin glargine-aglr) injection will be introduced at a price of $92 for a five pack of KwikPens®, which is a basal insulin that is biosimilar to Lantus® (insulin glargine) injection. This product is interchangeable with Lantus® and offers a 78% discount compared to Lantus®.

Insulin glargine is a prescription medication that is administered through self-injection. It is sold under the brand names Lantus, Basaglar, and Toujeo and does not have a generic version available.

Alcohol, anabolic steroids (such as testosterone), antipsychotics (such as aripiprazole, cariprazine, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone), basiliximab, and beta-blockers (such as atenolol, metoprolol, pindolol, propranolol, sotalol).

Basaglar and Lantus are injectable medications that contain insulin glargine, a type of long-acting insulin used to manage blood sugar levels in individuals with type 1 and type 2 diabetes.

The FDA has just given its approval for Rezvoglar, a new long-acting basal insulin, to be used by adults and children with type 1 diabetes, as well as adults with type 2 diabetes. Rezvoglar has been approved as a biosimilar to Sanofi’s Lantus, which is also an insulin glargine product.

Basaglar is produced using a different manufacturing method but has the identical amino acid sequence as Lantus.

Trulicity and Lantus are distinct diabetes medications with different mechanisms of action. Trulicity functions as a human GLP-1 receptor agonist, while Lantus is a synthetic version of a naturally occurring hormone. Both medications share common side effects such as weakness, lack of energy, and the potential for low blood sugar (hypoglycemia).

It is important to never mix Lantus with any other insulin or injectable medication in the same syringe. Doing so could alter the characteristics of Lantus and lead to unpredictable effects on blood sugar control. It is important to be aware that there are various types of insulins available.

REZVOGLAR is a prescription-only, synthetic insulin that has a long-lasting effect. It is used to manage elevated blood sugar levels in both adults and children with diabetes mellitus. Our company values your privacy and has a dedicated privacy statement. We also strive to ensure accessibility for all individuals and have an accessibility statement in place. For easy navigation, please refer to our sitemap.

Trulicity is expensive due to the lack of a generic version.

Insulin glargine, sold under the brand names Basaglar, Rezvoglar, and Semglee, is a type of long-acting human insulin analog. Rezvoglar and Semglee are specifically used to help regulate blood sugar levels in both adults and children with diabetes mellitus.

Novo Nordisk launched the MyInsulinRx program in September, offering eligible patients, including the uninsured, a 30-day supply of insulin for $35, within the price cap.

Semglee (insulin glargine-yfgn) was approved by the FDA in July 2021 as the first interchangeable biosimilar insulin product for Lantus (insulin glargine). It is a basal long-acting human insulin analog that is prescribed to manage patients with both type I and type II diabetes.

Human insulins like NPH, Regular insulin, and 70/30 mixtures are sold over the counter (OTC) in all states of the United States, except for Indiana.

The Purple Book is a comprehensive database that includes information on all FDA-licensed biological products overseen by the CDER, including licensed biosimilar and interchangeable products, as well as their reference products.

In November 2022, Rezvolgar became the fourth biosimilar to be granted an interchangeability designation.

REZVOGLARTM is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Additionally, Humalog®, Humulin®, and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Insulin manufacturers offer free insulin to uninsured individuals who meet income eligibility criteria through their patient assistance programs.

OTC insulin, also known as synthetic human insulin, is distinct from insulin analogs, which are newer forms of insulin. Trujillo states that the three primary types of over-the-counter insulin are regular insulin (short-acting), NPH (intermediate-acting), and a combination of NPH and regular insulin known as 70-30.

Tresiba has a duration of action of up to 42 hours, while Lantus has a duration of action of up to 24 hours. Tresiba may be more successful in preventing nighttime hypoglycemia in individuals with type 1 or type 2 diabetes. For more information, refer to the “How effective are Tresiba and Lantus?” section above.

Sanofi and Eli Lilly, major insulin manufacturers, have recently revealed their plans to implement a maximum out-of-pocket cost of $35 per month for their popular insulin products starting in late 2023 and early 2024. This move aims to enhance affordability and accessibility of this crucial medication. Furthermore, the U.S. government is also taking steps to ensure that more people can obtain this life-saving treatment.

The price of Rezvoglar subcutaneous solution (aglr 100 units/mL) is approximately $106 for a 15 milliliter supply, but may vary depending on the pharmacy.

Insulin glargine (Lantus) is a specially formulated, long-lasting human insulin alternative that addresses the limitations of existing ‘intermediate-acting’ insulins commonly used for basal insulin support.

Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr) are both biosimilar alternatives to Lantus. Basaglar (insulin glargine) is also a version of Lantus, but it is considered a follow-on biologic because it was approved before the biosimilar approval pathway for insulin was established.

Toujeo has a greater insulin concentration compared to Lantus. A Lantus SoloStar pen has 100 units of insulin in 1 mL of liquid, totaling 300 units of insulin per pen. Meanwhile, Toujeo pens have 300 units of insulin in 1 mL of liquid, making them three times more concentrated than Lantus pens.

If you have kidney or liver issues, there is a greater risk of experiencing hypoglycemia while using Lantus. It is important to discuss with your doctor whether Lantus is suitable for you. Additionally, if you have hypokalemia, using Lantus may exacerbate this condition.

Semglee, an insulin glargine biosimilar, is a medication that closely resembles the original drug in terms of effectiveness and safety. It is possible that your Medicare or insurance plan may cover Semglee, but there are also pharmacy coupons or cash prices available to help reduce the cost.

Starting from July 31, 2020, the original brand of insulin glargine, Lantus®, will no longer be produced and will be discontinued. However, there are two alternative options available. Optisulin® is another brand of insulin glargine produced by the same manufacturer as Lantus®, while Semglee® is a biosimilar insulin glargine produced by a different manufacturer.

Basaglar, an insulin glargine, shares the same chemical structure as Lantus, but it is manufactured differently. It is important to note that Lantus and Basaglar are not interchangeable, meaning your pharmacist cannot substitute Basaglar for Lantus without consulting your healthcare provider beforehand. However, there are various methods available to save on both Lantus and Basaglar.

Objective: The objective of this study is to compare the efficacy and safety of insulin glargine and human neutral protamine Hagedorn (NPH) insulin in reducing fasting blood glucose levels and preventing nocturnal hypoglycemic events in patients with type 2 diabetes.

Weight gain is a common side effect of Lantus treatment, as well as other types of insulin. Studies have shown that many people experience weight gain while using Lantus. This is because insulin helps your body store blood sugar, which can lead to weight gain.

In July 2022, the FDA approved a generic version of the long-acting insulin Tresiba (insulin degludec). Currently, the retail prices for generic insulin lispro, insulin aspart, and insulin glargine are less than half the price of Humalog, Novolog, and Lantus, respectively.

Do not use Lantus if you have an allergy to insulin or if you are experiencing low blood sugar or diabetic ketoacidosis. It is important to seek medical treatment for these conditions. Lantus is not suitable for individuals under the age of 6 and certain brands are intended for adult use only.

Insulin Glargine U-100 is an unbranded biologic that is indistinguishable from Lantus.